Prelude Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Prelude Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-15,000	Closed	-$590K	–	1252
2024 Q4	$590K	Buy	+15,000	New	+$708K	0.04%	540
2021 Q4	–	Sell	-2,117	Closed	-$185K	–	2004
2021 Q3	$237K	Buy	2,117 +2	+0.1%	+$251	0.01%	1264
2021 Q2	$342K	Buy	+2,115	New	+$257K	0.01%	1140
2020 Q4	–	Sell	-1,537	Closed	-$129K	–	1396
2020 Q3	$129K	Sell	1,537 -3,413	-69%	-$303K	0.01%	820
2020 Q2	$364K	Buy	+4,950	New	+$289K	0.02%	566
2019 Q3	–	Sell	-7,446	Closed	-$351K	–	1759
2019 Q2	$351K	Buy	+7,446	New	+$298K	0.02%	566
2018 Q3	–	Sell	-5,078	Closed	-$298K	–	1767
2018 Q2	$298K	Sell	5,078 -6,053	-54%	-$345K	0.02%	670
2018 Q1	$509K	Sell	11,131 -13,975	-56%	-$577K	0.04%	439
2017 Q4	$589K	Buy	+25,106	New	+$477K	0.05%	376

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Prelude Capital Management's CRSP Position: Q1 2025 in Review

Prelude Capital Management sold out of CRISPR Therapeutics (CRSP) in Q1 2025, closing a stake of 15,000 shares — an estimated $590K sold.

Prelude Capital Management first reported a position in CRSP in Q4 2017 and held it in 9 quarters. The position peaked at $590K in Q4 2024. 396 funds tracked by Wall St. Rank hold CRSP as of Q1 2025.

Prelude Capital Management reported no remaining CRISPR Therapeutics position as of Q1 2025 after selling out during the quarter.
Prelude Capital Management sold 15,000 CRISPR Therapeutics shares in Q1 2025, an estimated $590K.
Prelude Capital Management first reported a position in CRISPR Therapeutics in Q4 2017 and held it in 9 quarters.
Prelude Capital Management's CRISPR Therapeutics position peaked at $590K in Q4 2024.
396 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2025.

Based on Prelude Capital Management's 13F filing for Q1 2025, filed 15 May 2025.